Ritonavir

Hepatitis C, Chronic, Hepatitis C, Chronic, Obesity + 3 more

Treatment

1 FDA approval

20 Active Studies for Ritonavir

What is Ritonavir

Ritonavir

The Generic name of this drug

Treatment Summary

Ritonavir is a medication used to treat HIV infection by blocking the reproductive cycle of the virus. It is commonly used in combination with other protease inhibitors, such as lopinavir and atazanavir, to boost their effectiveness. It is available in liquid and capsule form. Ritonavir is also used in combination with other drugs to treat genotype 1a, 1b, and 4 chronic hepatitis C virus (HCV) infections, with or without cirrhosis. It is found in the FDA-approved products Viekira Pak and Technivie, as well as the Health Canada-approved product

Kaletra

is the brand name

image of different drug pills on a surface

Ritonavir Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Kaletra

Ritonavir

2000

50

Approved as Treatment by the FDA

Ritonavir, also called Kaletra, is approved by the FDA for 1 uses which include HIV .

HIV

Used to treat Human Immunodeficiency Virus Type 1 (HIV-1) Infection in combination with null

Effectiveness

How Ritonavir Affects Patients

Ritonavir is a medication used to treat HIV-1. It stops HIV from being able to cut itself into pieces, which stops the virus from reproducing and spreading. Ritonavir must usually be taken with at least two other HIV medications in order to be effective. Additionally, it helps the body absorb more of the other HIV medications, making them more effective.

How Ritonavir works in the body

Ritonavir blocks HIV proteins from being cut apart. Normally, proteins created by HIV are cut into pieces in order to form other proteins, but Ritonavir prevents this from happening. It does this by blocking the enzyme HIV proteinase from working. Ritonavir also stops the transport of other protease inhibitors by interfering with the P-glycoprotein and MRP efflux channels.

When to interrupt dosage

The proposed dose of Ritonavir is contingent upon the ascertained situation, including weight 40 kg or more, HIV (Human Immunodeficiency Virus) and Mild to Moderate COVID-19. The amount of dosage also depends on the mode of delivery (e.g. Oral or Tablet, film coated - Oral), as highlighted in the table beneath.

Condition

Dosage

Administration

COVID-19

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Hepatitis C, Chronic

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Hepatitis C, Chronic

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

HIV

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Obesity

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

SARS-CoV-2 Positive Patients

, 50.0 mg, 100.0 mg, 25.0 mg, 20.0 mg/mL, 80.0 mg/mL, 33.3 mg, 33.33 mg, 100.0 mg/mL

Tablet, film coated - Oral, Oral, Tablet, film coated, , Solution, Solution - Oral, Tablet, Tablet - Oral, Capsule - Oral, Capsule, Kit; Tablet, Kit; Tablet - Oral, Powder - Oral, Powder, Tablet, extended release - Oral, Tablet, extended release, Capsule, liquid filled - Oral, Capsule, liquid filled, Powder, for suspension, Powder, for suspension - Oral

Warnings

Ritonavir Contraindications

Condition

Risk Level

Notes

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulmonary Arterial Hypertension

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

Pulse Frequency

Do Not Combine

There are 20 known major drug interactions with Ritonavir.

Common Ritonavir Drug Interactions

Drug Name

Risk Level

Description

Alectinib

Major

The metabolism of Alectinib can be decreased when combined with Ritonavir.

Alfuzosin

Major

The serum concentration of Alfuzosin can be increased when it is combined with Ritonavir.

Amiodarone

Major

The metabolism of Amiodarone can be decreased when combined with Ritonavir.

Amodiaquine

Major

The metabolism of Amodiaquine can be decreased when combined with Ritonavir.

Anagrelide

Major

The metabolism of Anagrelide can be increased when combined with Ritonavir.

Ritonavir Toxicity & Overdose Risk

Very little is known about ritonavir overdose in humans. One person experienced tingling sensations after taking 1500mg/day for two days, while another developed kidney failure and an increase in white blood cells. Testing in animals suggests that it would take more than 20 times the recommended dose in humans to cause death in rats, and 10 times the recommended dose in mice. Additional side effects from taking too much ritonavir include liver damage, pancreatitis, and allergic reactions.

image of a doctor in a lab doing drug, clinical research

Ritonavir Novel Uses: Which Conditions Have a Clinical Trial Featuring Ritonavir?

Currently, 43 active trials are investigating the potential of Ritonavir to treat Chronic Hepatitis C Genotype 1a, Weight 40 Kg or More, and Human Immunodeficiency Virus (HIV).

Condition

Clinical Trials

Trial Phases

COVID-19

0 Actively Recruiting

Obesity

0 Actively Recruiting

HIV

39 Actively Recruiting

Phase 2, Phase 3, Phase 1, Early Phase 1, Not Applicable, Phase 4

Hepatitis C, Chronic

0 Actively Recruiting

Hepatitis C, Chronic

0 Actively Recruiting

SARS-CoV-2 Positive Patients

0 Actively Recruiting

Ritonavir Reviews: What are patients saying about Ritonavir?

4.3

Patient Review

10/11/2022

Ritonavir for experimental treatment for COVID-19

I started taking this medication when I had my first onset of symptoms for COVID-19 in October 2022. My sister, who was also ill at the same time, did not take the medication. We both saw our conditions improve within a day of each other. I would recommend this medication to anyone looking to limit the worsening of their infection. The only negative effect I experienced was a strong metallic taste, so enjoy your food prior to dosage!

1.7

Patient Review

4/23/2022

Ritonavir for experimental treatment for COVID-19

After only two days on this medication (four doses), I experienced an intense metallic taste in my mouth and overwhelming fatigue. Additionally, I felt generally unwell and had to take Tums to find relief from the full feeling in my stomach. I called my medical doctor and they advised me to stop taking the medication. The only Covid symptoms I was experiencing were a runny nose and occasional sneezing.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about ritonavir

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does ritonavir have side effects?

"Ritonavir has the potential to cause some very serious side effects, including pancreatitis (inflammation of the pancreas), heart rhythm problems, severe skin rash and allergic reactions, liver problems, and drug interactions."

Answered by AI

What drugs contain ritonavir?

"There are several brands of protease inhibitors, antiviral boosters, and antiviral combinations. Norvir is one brand of antiviral booster, and Viekira XR and Viekira Pak are two brands of antiviral combination. AccessPak for HIV PEP Expanded with Kaletra is a brand of antiretroviral therapy, and Kaletra is a brand of protease inhibitor. Paxlovid is a brand of antiviral booster, and Technivie is a brand of antiviral combination."

Answered by AI

What is the drug ritonavir used for?

"It helps keep HIV from multiplying and increasing the amount of HIV in your body. Ritonavir is also used to increase the effectiveness of other medicines used to treat HIV.

Ritonavir is used to treat HIV, the virus that causes AIDS, in conjunction with other drugs. Ritonavir does not cure HIV or AIDS, but prevents the virus from replicating and thus slowing the progression of the disease. Ritonavir is also used to bolster the effectiveness of other drugs used to treat HIV."

Answered by AI

Is ritonavir used to treat Covid?

"The EPIC-HR trial showed that people who started taking ritonavir-boosted nirmatrelvir within 5 days of their COVID-19 symptoms appearing were 89% less likely to be hospitalized or die from the virus within 28 days, compared to those who took a placebo."

Answered by AI

Clinical Trials for Ritonavir

Image of VA Greater Los Angeles Healthcare System, West Los Angeles, CA in West Los Angeles, United States.

EBQI Strategies for Women's Health

Any Age
All Sexes
West Los Angeles, CA

Women Veterans are the fastest growing segment of VA users, with most users in midlife. This dramatic growth has created challenges for VA to ensure that appropriate services are available to meet women Veterans' needs, and that they will want and be able to use those services. Furthermore, few VA improvement efforts have focused on women Veterans' health and health care in midlife. The EMPOWER QUERI 3.0 Program is a cluster randomized type 3 hybrid implementation-effectiveness trial testing two strategies designed to support implementation and sustainment of evidence-based practices for women Veterans in at least 18 VA facilities from 4 regions.

Waitlist Available
Has No Placebo

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Alison B Hamilton, PhD MPH

Image of Brigham and Womens Hospital in Boston, United States.

Chia Seeds for Breastfeeding

18 - 45
All Sexes
Boston, MA

The investigators' over-arching hypothesis is that mechanical and compositional properties of chia seeds supplemented during lactation diminish obesity-induced intestinal inflammation and barrier dysfunction. The investigators hypothesize these changes will result in: 1) reduced maternal systemic inflammation (serum CRP and IL-6) and increased gut microbial diversity and richness, 2) reduced HM fat and inflammatory markers, metrics the research team have demonstrated differ in tandem with maternal metabolic health and 3) improved infant growth/body composition. To test these hypotheses, investigators will evaluate chia seed supplementation during lactation in a 6wk multi-site pilot RCT (Aim 1) and through translational studies using human enteroids (Aim 2).

Waitlist Available
Has No Placebo

Brigham and Womens Hospital (+1 Sites)

David A Fields, Phd

Have you considered Ritonavir clinical trials?

We made a collection of clinical trials featuring Ritonavir, we think they might fit your search criteria.
Go to Trials
Image of Public Health Research Center: Clinical Exercise Research Center in Columbia, United States.

Pistachio Snacking for Obesity

25 - 45
All Sexes
Columbia, SC

The purpose of this study is to evaluate the effects of pistachio snacking on metabolic flexibility (at rest, during exercise, and in post-exercise recovery) in healthy overweight and obese adults. Secondary goals include evaluating effects on changes in diet quality, sleep characteristics, physical activity, and hormonal health in women. In randomized order, participants will complete four days of pistachio snacking and four days of normal dietary habits (control). For both conditions, primary outcomes of resting substrate metabolism, metabolic flexibility during exercise, and post-exercise substrate metabolism will be measured pre-post intervention via indirect calorimetry. Secondary outcome of diet quality (kcal, carb, fat, protein) will be measured pre-post intervention via diet log. Exploratory outcomes of daily physical activity (steps, intensity), nightly sleep characteristics (quantity, quality, latency, efficiency), and daytime sleepiness and hunger.

Recruiting
Has No Placebo

Public Health Research Center: Clinical Exercise Research Center

Katie R Hirsch, PhD

Image of People Science in Los Angeles, United States.

CLB101 for Gut Health in Obesity

18 - 65
All Sexes
Los Angeles, CA

Anaerostipes caccae CLB101TM️ is a next-generation probiotic isolated from healthy humans. It was shown to be in decreased abundance in people with protein-based food sensitivities/allergies. CLB101TM️ is different from most commercially available probiotics in that it directly produces butyrate. Butyrate is a naturally occurring small molecule found in the gut of healthy individuals, and it has been shown to provide clinical benefits including strengthening the gut lining, providing immune health, and supporting a balanced microbiome. The rationale for developing CLB101TM️ is to provide a probiotic that generates butyrate in the targeted intestinal locations where it can optimally benefit cells that line the gut.

Waitlist Available
Paid Trial

People Science

Naoh Craft, MD

ClostraBio Inc.

Have you considered Ritonavir clinical trials?

We made a collection of clinical trials featuring Ritonavir, we think they might fit your search criteria.
Go to Trials
Image of Miles Square Health Center Chicago in Chicago, United States.

Food is Medicine for High Blood Pressure and Obesity

Any Age
All Sexes
Chicago, IL

The goal of this clinical trial is to treat both hypertension and obesity in adults using a food is medicine framework. Participants will be randomized 1:1 to FIM+DASH or usual-care control. The 24-week trial includes a 12-week FIM+DASH intervention followed by a 12-week maintenance period and leverages existing partnerships with community-based organizations for home food delivery and culinary skill-skill building. The main questions it aims to answer are: (1) What is the effect of FIM+DASH vs. usual care control on blood pressure? (2) What is the effect of FIM+DASH vs. usual care control on DASH diet adherence (diet quality), body weight, and waist circumference? (3) How to identify factors associated with the sustainability and scalability of FIM+DASH in real-world settings?

Phase 2
Waitlist Available

Miles Square Health Center Chicago (+3 Sites)

Image of Local Restaurant Site in Bryan, United States.

Menu Labeling for Healthy Habits and Diet

18+
All Sexes
Bryan, TX

This study evaluates the impact of culturally tailored menu labeling interventions on psychosocial factors and ordering behavior among customers in two independently owned Hispanic restaurants in East-Central Texas. Participants will be exposed to one of three sequential menu conditions at each restaurant: (1) a standard menu without nutrition information, (2) a paper menu with bilingual nutrition labels, or (3) a digital menu app enhanced with Augmented Reality (AR) and Artificial Intelligence (AI) providing interactive nutrition guidance. The study will assess whether menu formats influence nutrition literacy, decision-making confidence, self-efficacy, attitudes, behavioral intentions, and actual ordering behavior. Data will be collected through surveys, purchase receipts, and app interaction logs.

Recruiting
Has No Placebo

Local Restaurant Site

Hyunjung Lee, PhD

Have you considered Ritonavir clinical trials?

We made a collection of clinical trials featuring Ritonavir, we think they might fit your search criteria.
Go to Trials